Accelerating the Commercialization of Cancer Research Results
The Canadian Cancer Society (CCS) and the Creative Destruction Lab (CDL) have launched a new world-class accelerator program for entrepreneurs and researchers developing innovations to improve the cancer experience globally and throughout the cancer care continuum. This program will educate, coach, finance and inspire seed-stage oncology-focused companies by pairing them with mentors, industry leaders and subject matter experts. Over 9 months and 5 sessions, accepted startups will be supported to tighten their strategic objectives, raise capital and engage with partners in the field. CDL Cancer will operate through the CDL Health and CDL Neuro streams based in CDL-Toronto (University of Toronto) and CDL-Vancouver (University of British Columbia) and is now accepting applications for the CDL 2022/23 Program Year. CDL Cancer is a foundational component of CCS’s new Centre for Cancer Prevention and Support, a national hub of research and innovation for cancer prevention and support services.

The CIHR Institute of Cancer Research is pleased to announce the open call for applications for its 2025 Early Career Researcher (ECR) Workshop, in partnership with the Canadian Cancer Research Alliance, Canadian Cancer Society, Cancer Research Society, Ontario Institute f...
Participants and supporters of the 2021 PIP are pleased to announce that Dr. Stéphanie Bernard, a postdoctoral fellow at the University of Alberta in the Faculty of Rehabilitation – Physical Therapy, is the winner of the inaugural PIP Small Grant Competition, a one-year $15,000 grant...